Gyroscope Therapeutics
Claire Harris is an accomplished immunologist with extensive experience in both academia and industry. Currently serving as Vice President at NewCo and as a Board Member for the European Complement Network, Claire also holds positions as an Honorary Professor at Cardiff University and a Visiting Professor at Newcastle University, where research focuses on molecular immunology and complement therapeutics. Previous roles include Executive Director of Complement Translational Research at Novartis Institutes for Biomedical Research and Vice President at Gyroscope Therapeutics, specializing in innovative gene therapies for age-related macular degeneration. Claire's leadership is further evidenced by contributions to the International Complement Society and involvement in major academic positions across several universities and pharmaceutical companies. Claire holds a PhD in Immunology from the University of Cambridge and a BSc in Biochemistry from the University of York.
This person is not in any offices
Gyroscope Therapeutics
Gyroscope Therapeutics is a clinical-stage retinal gene therapy company developing gene therapy beyond rare diseases to treat a leading cause of blindness, dry age-related macular degeneration (AMD).